Utilizing multi-omics analysis, a new signature has been identified and validated for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma, which is based on tumor mutation burden

Utilizing multi-omics analysis, a new signature has been identified and validated for predicting prognosis and response to immunotherapy in lung squamous cell carcinoma, which is based on tumor mutation burden

Abstract Immunotherapy is used extensively in treating non-small cell lung cancer (NSCLC) patients. Nevertheless, in contrast to lung adenocarcinoma (LUAD), the endeavors to develop effective targeted treatments for lung squamous cell carcinoma (LUSC) have not yielded positive outcomes. Hence, it is...

Full description

Saved in:
Bibliographic Details
Main Authors: Dongguang Wang, Yan Wang, Yiqun Peng, Liang Peng
Format: Article
Language:English
Published: Springer 2025-04-01
Series:Discover Oncology
Subjects:
TMB
LUSC
SYNE1
TTN
Immune infiltrates
Immunotherapy
Online Access:https://doi.org/10.1007/s12672-025-02166-2
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s12672-025-02166-2

Similar Items